# Sermorelin Legal — A reading of the U.S. regulatory record on sermorelin acetate > An editorial overview of sermorelin's legal status in the United States: the discontinued FDA NDA, the 2013 Federal Register non-safety determination, the 503A compounding pathway, DEA non-scheduling, and the WADA S2.2.4 prohibition. Informational only. Sermorelin acetate sits in an unusual jurisdictional pocket: a twice-approved FDA drug whose finished product was pulled in 2008 for commercial reasons, a substance the DEA does not schedule, and a peptide the World Anti-Doping Agency prohibits at all times. This site reads that record line by line. ## // SHORT_VERSION :: WHAT_THIS_IS Sermorelin (GHRH 1-29) is a 29-amino-acid synthetic peptide that mimics the hormone the hypothalamus uses to tell the pituitary to release growth hormone. It was sold in the United States as a prescription drug — brand name Geref — under two FDA approvals (1990 for diagnosis, 1997 for pediatric treatment) before the sponsor pulled it from the market in 2008 for commercial reasons. The FDA formally confirmed in 2013 that the withdrawal had nothing to do with safety or efficacy. Today, no finished sermorelin product is FDA-approved. It moves through licensed 503A compounding pharmacies under an interim FDA policy, the DEA does not schedule it, and the WADA Prohibited List enumerates it under section S2.2.4. That layered jurisdictional picture — agency by agency, question by question — is what this site reads. For effects and safety cautions, see the [effects page](/effects). ## What sermorelin is, in one paragraph Sermorelin is the amidated synthetic form of the first 29 amino acids of human growth hormone-releasing hormone, abbreviated GHRH(1-29)-NH2 [1]. The native hypothalamic hormone is 44 amino acids long, but the (1-29) fragment carries essentially all of the receptor binding and growth-hormone-releasing activity of the full molecule [1][12]. Sermorelin binds the GHRH receptor on anterior-pituitary somatotrophs, triggers a Gs-coupled cAMP/PKA cascade, and prompts the pituitary to release endogenous growth hormone in a discrete pulse [7][12]. Because the pituitary stays in the loop, the body's somatostatin negative-feedback architecture is preserved — a point that has structured much of the clinical interest in sermorelin and, later, in the broader GHRH-analog class [7]. ## Why the legal status is the interesting story Most peptides in the current research-use conversation never held an FDA approval. Sermorelin held two. The U.S. Food and Drug Administration first cleared sermorelin acetate in 1990 as a diagnostic provocative agent for pituitary growth-hormone evaluation, and again in 1997 as a once-daily subcutaneous treatment for pediatric idiopathic growth hormone deficiency [6][13]. The sponsor voluntarily discontinued both new drug applications in 2008. FDA's marketing approval was administratively withdrawn effective June 18, 2009 [13]. That sequence — two approvals, then a commercial exit — is what makes sermorelin's legal posture distinctive. In March 2013 the agency published a formal Federal Register notice (78 FR 14296) determining that the withdrawal was 'not for reasons of safety or effectiveness' [13]. The legal effect of that determination is procedural but consequential: it preserves the pathway for an Abbreviated New Drug Application on the same strengths, and it informs the regulatory treatment of sermorelin as a substance eligible for consideration in the FDA's 503A compounding framework pending final rulemaking [14]. No other branch of U.S. drug law treats sermorelin as a controlled substance. The Drug Enforcement Administration's published schedules under 21 CFR 1308 do not enumerate sermorelin in any of Schedules I through V [17]. That distinguishes it sharply from recombinant human growth hormone, which sits under the special restrictions of 21 USC 333(e) whenever it moves outside FDA-approved indications [17]. Sermorelin remains a prescription-only legend drug — legal to possess by valid prescription, illegal to distribute without one. ## The jurisdictional map Four agencies and one international code govern the answer to 'is sermorelin legal,' and they reach different conclusions because they ask different questions. The FDA, asking whether a finished drug product is approved for U.S. marketing, currently answers no — the original sermorelin acetate NDAs are discontinued and no replacement approval exists [13]. The same agency, asking whether the bulk drug substance may be used by 503A compounding pharmacies pursuant to a patient-specific prescription, has historically treated sermorelin as eligible pending final Pharmacy Compounding Advisory Committee rulemaking [14]. The DEA, asking whether the substance has abuse potential warranting scheduling, has not placed sermorelin on any controlled-substances schedule [17]. The World Anti-Doping Agency, asking whether the substance offers a performance advantage in sport, enumerates sermorelin by name under Section S2.2.4 ('Growth Hormone Releasing Factors') of the 2025 Prohibited List, banned in- and out-of-competition for all WADA-code athletes [15][16]. The European Medicines Agency has never granted sermorelin a centrally authorized marketing approval; national magistral preparation rules apply where permitted [22]. If the cyberpunk metaphor of this site is useful for anything, this is it: each agency is a separate channel, and a reader who wants the actual legal answer for a specific use needs to know which channel they are reading. ## What this site is, and what it is not Sermorelin Legal is an independent editorial publisher. It summarizes the peer-reviewed and regulatory record on sermorelin acetate. It is not a clinic, not a law firm, not a pharmacy, and not a vendor. It does not sell sermorelin or any other substance, and it is not affiliated with any compounder, prescriber, or manufacturer. Every regulatory claim on this site is tied to a named primary source — a Federal Register notice, an FDA guidance document, a WADA technical document, a peer-reviewed paper, or the Controlled Substances Act itself. For the question of whether any specific use is lawful for any specific person in any specific jurisdiction, consult a licensed attorney or pharmacist in the relevant state. Nothing on this site is legal advice. --- An independent reading of the regulatory and scientific record — not legal advice, not medical guidance.